NephCure Kidney International has named Joshua Tarnoff as its new CEO, the organization recently announced.

According to a press release, Tarnoff most recently served as the CEO and president of Complexa Inc. for 7 years. Tarnoff has also held executive positions at Viropharma Inc. and AstraZeneca.

“It’s the right time to build on the tremendous accomplishments that NephCure has achieved to date and be able to work directly with patients to help advance cures for nephrotic syndrome and [focal segmental glomerulosclerosis] FSGS,” Tarnoff said in the release. “I’m looking forward to working with the NephCure staff, board, pharmaceutical partners and most importantly, the patient community, to bring treatments to the market for this debilitating and chronic kidney disease.”

NephCure is focused on partnering with trial sponsors, educating patients around clinical trial participation and engaging a “trial-ready” community to ensure these trials are successfully recruited and completed, the organization noted. “Only by effectively filling and completing these trials can new treatments be brought to the patient community,” according to the release.